Granules India is currently trading at Rs. 621.45, up by 7.45 points or 1.21% from its previous closing of Rs. 614.00 on the BSE.

The scrip opened at Rs. 602.10 and has touched a high and low of Rs. 623.90 and Rs. 602.10 respectively. So far 67138 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 640.00 on 25-Mar-2026 and a 52 week low of Rs. 412.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 638.50 and Rs. 600.25 respectively. The current market cap of the company is Rs. 15409.25 crore.

The promoters holding in the company stood at 38.82%, while Institutions and Non-Institutions held 31.03% and 30.15% respectively.

Granules India’s wholly-owned subsidiary -- Granules Pharmaceuticals, Inc. (GPI), located in Chantilly, Virginia, US, has completed a routine current Good Manufacturing Practices (cGMP) audit by the US Food and Drug Administration (FDA) with four Form 483 observations. This inspection was conducted from March 30 to April 3, 2026 and marks the second USFDA inspection at the Chantilly facility in last one year. The observations are related to procedural matters and no data integrity - related observations were reported during the inspection.

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).